The Global & Premier mRNA Conference for Science Innovation & Biopharma Success
With 1,988 mRNA assets advancing through the global pipelines, the field has never moved faster – making the 6th mRNA‑Based Therapeutics Summit perfectly timed to spotlight the breakthroughs reshaping the future of mRNA medicines. This year’s forum will showcase pivotal new data, emerging platforms in linear mRNA, circular and self-amplifying RNA, and clinical progress across oncology, rare diseases, autoimmune conditions, and more, as mRNA continues to expand into unprecedented therapeutic territory.
This remains the place to connect with key mRNA players and decision makers, ignite new partnerships and refine your strategy to unlock the full therapeutic potential of mRNA. From next‑gen vaccine design to pioneering protein replacement, cell and gene therapeutics and transformative delivery technologies, this forum equipped teams with the insights and connections needed to accelerate candidates toward clinical and commercial success – and ultimately deliver life‑changing impact for patients.
Unmissable Highlights Included
CEO & mRNA Leaders Think Tank
On Day One, dive straight into the pulse of the mRNA revolution as the field’s most influential mRNA‑focused biotechs and pharma leaders take the stage. Hear their bold perspectives on the current state of play, how they’re shaping pipeline strategy, and the pivotal decisions driving the mRNA roadmap for 2026 and beyond.
You Can Hear From:
- Daniel Getts, Chief Executive Officer, CREATE Medicines
- Peter Weinstein, Chief Executive Officer, Circurna
- Alex Zinoviev, Director, mRNA Platform, Eli Lilly
- Nathaniel Wang, Chief Executive Officer, Replicate Bioscience
Business Development & Investors Outlook
With acquisitions, strategic collaborations, and fresh investment pouring into the mRNA space, the field is experiencing a new wave of momentum. At this year’s meeting, the leaders behind these headline‑making deals will pull back the curtain on what’s driving this surge, what it signals for the future of the industry, and – most importantly – how these advances will accelerate meaningful impact for patients.
- Julia Lee, Senior Director of Search & Evaluation – Vaccines & ID, GSK
- Kathy Fernando, Chief Business Officer, Replicate Bioscience
- Christina Vorvis, Director, Abbvie Ventures
- David Kolesky, Principal, MPM BioImpact
Regulators Take the Stage: What You Need to Know
With the prospect of accelerated approval pathways for cell and gene therapies, alongside multi‑use platform technologies and with minimal CQA impact, it’s more critical than ever to understand the regulatory perspective. Hear directly from regulatory leaders on how they interpret current mRNA‑specific guidelines, what expectations they have for emerging developers, and how agencies aim to partner with industry on the path toward the first approved mRNA‑based therapeutic.
- Marco Cavaleri, Head of Biological Health Threats & Vaccine Strategy, European Medicine’s Agency
- Sai Prathyusha Bhamidipati, Director of Regulatory CMC, Moderna
Divide & Conquer
The mRNA field is vast, which is why we have worked closely with subject-matter experts to identify the key challenges facing the community. From C-level executives to scientists, the problems may differ, but together, we can tackle them.
By splitting into 3 tracks (Discovery, Pre-Clinical & Clinical Development and Manufacturing & CMC), our speakers have tailored their presentations to dive into specific challenges for those stages of development.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned.
A snapshot of key sessions featured in each track across the 2026 program:
Pre-Conference Day:
Unlocking mRNA as a Key Tool for In Vivo CAR T Cell Programming & Potential for Combating Autoimmune & Wider Diseases
- David Weinberg, Chief Executive Officer, Parcelbio
- Nikola Ivica, Co-Founder & Chief Scientific Officer, InnDura Therapeutics
Discovery
Unravelling Novel RNA Modality Approaches to Improve Potency, Tolerability & Protein Expression
- Cory Sago, Chief Executive Officer, Amplitude Therapeutics
- Yingzhong Li, President, SunVax mRNA Therapeutics
Pre-Clinical & Clinical Development
Unlocking mRNA as a Key Tool for In Vivo CAR T Cell Programming & Potential for Combating Autoimmune & Wider Diseases
- David Weinberg, Chief Executive Officer, Parcelbio
- Nikola Ivica, Co-Founder & Chief Scientific Officer, InnDura Therapeutics
Manufacturing & CMC
Innovating the Process: Combating IVT Impurities to Advanced Monitoring & Digital Twins to Improve Efficiency & Manufacturing at Scale
- Nikhil Adi, Senior Principal Scientist, Pfizer
- Akshay Phulgirkar, Senior Manager, Moderna
Explore the Full Event Guide
- 350+ mRNA Players Including Moderna, Pfizer, Sanofi and more
- 50+ Data-Driven Case Studies on the End-to-End of mRNA Development
- 3 Tracks of End-to-End Scientific Content
- AI mRNA Design & Next-Gen Delivery Focus Days
- Unrivalled Networking & Partnering Opportunities
- The World's Largest Industry-Led mRNA Forum
Brand New Companies for 2026
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the mRNA innovations during our packed agenda, interactive roundtables, and new CEOs & investor panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of mRNA biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.